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Abstract 
Lysophosphatidic acid (LPA) influences many physiological processes, such as 
brain and vascular development. It is associated with several diseases including ovarian 
cancer, breast cancer, prostate cancer, colorectal cancer, hepatocellular carcinoma, 
multiple myeloma atherosclerotic diseases, cardiovascular diseases, pulmonary 
inflammatory diseases and renal diseases.  LPA plasma and serum levels have been 
reported to be important values in diagnosing ovarian cancer and other diseases. However, 
the extraction and quantification of LPA in plasma are very challenging because of the 
low physiological concentration and similar structures of LPA to other phospholipids. 
Many previous studies have not described the separation of LPA from other 
phospholipids, which may make analyses more challenging than necessary.  
We developed an SPE extraction method for plasma LPA that can extract LPA at 
high purity. We also developed an HPLC post-column fluorescence detection method that 
allows the efficient quantification of LPA. These methods were used in a clinical study 
for ovarian cancer diagnosis to help validate LPA as a biomarker of ovarian cancer. 
Moreover, molecular imprinted polymers (MIPs) were designed and synthesized as 
material for the improved extraction of LPA. Compared to the commercially available 
materials, the MIP developed shows enhanced selectivity for LPA. The extraction was 
overall relatively more efficient and less labor-intensive.  
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Chapter 1 Introduction 
 
1.1 Structure and formation of LPA 
Lysophosphatidic acid (LPA) is a phospholipid that consists of a phosphate head 
group, a glycerol backbone and an alkyl chain structure. LPA has many subspecies based 
on differing length and saturation of the alkyl chain. The structures of five major LPA 
species are shown in Figure 1.1. 
 
 
 
Figure 1.1  Structures of lysophosphatidic acids (LPAs). 
LPA can be produced by at least two distinct enzymatic mechanisms. The main 
source is the hydrolysis of lysophosphatidylcholine (LPC) by lysophospholipase D (lyso-
PLD), such as autotaxin (ATX). It can also be generated from the hydrolysis of PA via 
phospholipase A1 (PLA1) or phospholipase A2 (PLA2). 
1 Figure 1.2 shows the two 
mechanisms using LPA 18:1 as an example. 
  2 
 
Figure 1.2  Two distinct enzymatic mechanisms of LPA generation. 
As a bioactive phospholipid, LPA can activate specific cell-surface G protein-
coupled receptors that initiate many cellular processes, such as cell proliferation 2 3, 
migration 4 and platelet aggregation 5,6. LPA also influences many physiological 
processes such as brain development 7, vascular development 8, wound healing and 
pathological conditions, including autoimmune disorders and tumor metastasis. 9 10 11 
1.2 LPA as a biomarker of ovarian cancer 
There are more than 20,000 new cases of ovarian cancer in the US every year. 
More than 60 % of all patients die from this disease. 12 The early stages of the disease are 
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difficult to diagnose because of a lack of specific symptoms. The majority of patients are 
diagnosed with stage III or IV disease, while ca. 30% of are diagnosed at stage I or II. An 
important determinant of ovarian cancer survival is the stage of the disease at diagnosis. 
13 The five-year survival relative survival rates are more than 90% for stage I, while only 
less than 10% for stage IV. (Figure 1.3) 
 
Figure 1.3  Ovarian cancer five-year relative survival rates. 
Currently, there is no accurate and effective screening test for the early detection 
of ovarian cancer. Pelvic exam is a common way to diagnose ovarian cancer. However, it 
only detects the disease occasionally and usually when the disease is advanced. The 
combination of a thorough pelvic exam, an ultrasound and a blood test for the biomarker 
CA125 are suggested, but are not proven completely effective yet.  
  4 
In 1998, Xu et al. found that increased LPA levels in human plasma were related 
to ovarian cancer. LPA as a biomarker showed advantages in early stage detection 
compared to CA125, which was used as the conventional biomarker control for ovarian 
cancer diagnosis. According to their results, 90% of the stage I patients have an elevated 
level of LPA while only 20% have an elevated level of CA125. 14 Figure 1.4 shows the 
percentage of patients that have elevated levels of LPA and CA125 in different stages.  
 
 
 
Figure 1.4  Comparison of LPA and CA125 as biomarkers for ovarian cancer at different stages. 
After this result was published, many other groups studied the correlation of LPA 
and ovarian cancer and reported LPA as a perspective marker 15 16, 17 18, 19 although some 
groups had different opinions 20. Liu et al. 21 reported that LPA promoted ovarian cancer 
progression by inducing MMP-9 expression and MMP-9-catalyzed E-cadherin 
ectodomain shedding. 
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1.3 LPA and other diseases 
LPA influences many physiological processes, such as brain7 and vascular 
development 8 and is involved in many diseases apart from ovarian cancer 14, such as 
breast cancer 22, prostate cancer 23, colorectal cancer 24, hepatocellular carcinoma 25, 
multiple myeloma 26 atherosclerotic diseases 27 28, cardiovascular diseases 29, pulmonary 
inflammatory diseases 30, renal diseases 31, 32.  
1.4 Challenge of LPA analysis in human plasma 
Quantification of LPA in plasma is very challenging because of its low 
physiological concentration. The concentration of phospholipids in human plasma is > 
2000 µM 33. Among the several classes of phospholipids that are present in human 
plasma, LPA represents a relatively very small fraction, and reported concentrations of 
total LPA vary. A generally reported range is 1-5 µM 34.  This makes it very challenging 
for the selective isolation and enrichment of these analytes. Moreover, some studies 
showed that not total LPA, but certain subspecies of LPA are the biomarkers of ovarian 
cancer. 17 Thus, it is necessary to separate and quantify each individual LPA species. 
Additionally, other phospholipids could interfere both the extraction and detection 
because of their similar structures to LPA. For example, the lysophospholipids such as 
lysophosphatidylethanolamine (LPE), lysophosphatidylcholine (LPC) and 
lysophosphatidylserine (LPS) have similar structures to LPA, with only different head 
groups. Phosphatidic acids (PA) have the same head group as LPA, but have an extra 
alkyl chain than LPA.  Structures of representative lysophospholipids are shown in 
Figures 1.5 and 1.6. Moreover, the concentrations of some of these phospholipids are 
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much higher than LPA in human plasma. For example, the concentration of LPC is 
around 300 µM.35 It is not only difficult to quantify LPA in the presence of LPC, but it is 
also challenging to separate them because of the similar properties. 
 
Figure 1.5  Structure comparison of PA and LPA. 
  7 
 
Figure 1.6  Structures of representative lysophospholipids. 
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Chapter 2 Extraction and HPLC post-column quantification of LPA in plasma 
 
2.1 Introduction 
HPLC post-column fluorescence probe-assisted methods have been reported for 
phospholipids previously 36-38. However, they had not found utility in LPA analyses. A 
commercially available fluorescent probe 4-(4-(dihexadecylamino) styryl)-N-
methylpyridinium iodide (DiA) is used in this study as a post-column reagent for the 
detection and quantification of LPA. Structure of DiA is shown in Figure 2.1 One may 
separate and quantify six individual LPA subspecies at physiological levels in plasma 
with a C-8 column in 15 minutes. In contrast to the currently used liquid 
chromatography–mass spectrometry (LC-MS) methods, LPA levels obtained by optical 
method are not susceptible to ionization-related issues. 
To date, a number of separation and detection methods to determine LPA levels 
have been developed. In 1998, Xu et al. 14 used a gas chromatography (GC) method to 
quantify total levels of LPA in plasma. Chen et al.39 used capillary electrophoresis (CE) 
to quantify individual LPAs with an indirect ultraviolet (UV) detection method. However, 
to separate LPA from other lipids before detection, many of these early studies employed 
two-dimensional thin layer chromatography (TLC). 14, 15, 39, 40 High performance liquid 
chromatography (HPLC) has been used to separate LPA. Solid supports have included 
[Wang, J. et al. Simple enrichment and analysis of plasma lysophosphatidic acids. Analyst 138, 
6852-6859 (2013).] - Reproduced by permission of The Royal Society of Chemistry. 
http://pubs.rsc.org/en/content/articlelanding/2013/an/c3an01168b#!divAbstract 
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normal phase (used in hydrophilic interaction chromatography), reversed phase (C8, C18) 
and diol-bonded phases. 
 For example, Holland et al.41 used a diol-bonded phase to separate LPA from 
other phospholipid classes with evaporative light-scattering detection (ELSD). This 
avoids the 2-D TLC step; however, LPA recovery is 53.4% and there is no effort to 
separate LPA subspecies. LC-MS has also been used to quantify LPAs. 3 More recently 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) has become the method 
of choice.15, 42, 43 However, there are reports that LC-MS/MS methods currently have 
some drawbacks. First, not all endogenous matrix components are efficiently separated 
from the target analytes.  This leads to matrix effects that hamper the efficiency and 
reproducibility of the ionization process.44-47 Phospholipids, especially 
glycerophosphocholines and lysophosphatidylcholines, are cited as the major causes of 
matrix effects due to their highly ionic character.  This affects the electrospray MS source 
by either suppressing or enhancing ionization. This cannot be compensated for by adding 
internal standards, including isotopically labelled phospholipids. Wang et al.45 
demonstrated that slight differences in retention times between the analyte and the 
isotopically-labelled internal standard cause differences in ion suppression between the 
two. In their study, the results vary up to 52% in peak areas from one plasma sample to 
another because of matrix effects resulting in up to 18.9 % of variation in concentration. 
Matrix effects may also result in retention time shifts, elevated baselines and divergent 
calibration curves. Second, conversion of lysophosphatidylcholine (LPC) and 
lysophosphatidylserine (LPS) to LPA occurs at the ion source of electrospray ionization 
tandem mass spectrometry. Shan et al.48 found that unidentified compounds in plasma 
  10
produce the same parent-to-daughter ion transition as LPA in a direct flow injection 
liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-
ESI/MS/MS) method and could reduce the accuracy of the analysis of LPA. Zhao et al.49 
later reported that LPC and LPS lose their respective choline or serine moieties at ion 
source to generate LPA-like signals. 
In order to overcome the limitations described above, we propose a 
straightforward method combining a modified Bligh and Dyer 50  procedure with a solid 
phase extraction (SPE) protocol.  This isolates plasma LPA effectively enough to permit 
the rapid detection of each of the subspecies via a standard HPLC fluorescence detector.  
HPLC post-column fluorescence probe-assisted methods have been reported for 
phospholipids previously; 36-38 however, they had not found utility in LPA analyses. A 
commercially available fluorescent probe 4-(4-(dihexadecylamino) styryl)-N-
methylpyridinium iodide (DiA) is used in this study as a post-column reagent for the 
detection and quantification of LPA. One may separate and quantify six individual LPA 
subspecies at physiological levels in plasma with a C8 column in 15 minutes. In contrast 
to the currently used LC-MS methods, LPA levels obtained by optical method are not 
susceptible to ionization-related issues. 
2.2 Experimental 
2.2.1  Materials  
All lysophosphatidic acids including 1-myristoyl-2-hydroxy-sn-glycero-3-
phosphate (LPA 14:0), 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphate (LPA 16:0), 1-
  11
heptadecanoyl-2-hydroxy-sn-glycero-3-phosphate (LPA 17:0), 1-stearoyl-2-hydroxy-sn-
glycero-3-phosphate (LPA 18:0), 1-oleoyl-2-hydroxy-sn-glycero-3-phosphate (LPA 18:1) 
and 1-arachidonoyl-2-hydroxy-sn-glycero-3-phosphate (LPA 20:4) were purchased from 
Avanti Polar Lipids (Alabaster, AL, USA). 4-(4-(Dihexadecylamino) styryl)-N-
methylpyridinium iodide (DiA) was purchased from AnaSpec (Fremont, CA, USA). 
HPLC grade MeOH was purchased from Fisher Scientific. Ultra pure water was obtained 
from a Milli-Q™ system. Phosphoric acid and monosodium phosphate were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Waters OASIS™ HLB (3 cc, 60 mg, 30 μm) 
SPE cartridges were purchased from Waters Corporation (Milford, MA, USA). 
Lyophilized Human Plasma was purchased from Sigma-Aldrich. Human plasma was 
collected by Lampire Biological Laboratories Inc., from female donors, processed to 
obtain platelet-free plasma, and frozen at -80 ºC. 
2.2.2 Instrumentation 
Fluorescence measurements were performed on a Cary Eclipse™ fluorescence 
spectrophotometer, and absorption spectra performed on a Cary 50™ UV-Vis 
spectrophotometer (Agilent Technologies).  The HPLC system consists of a 1525 binary 
HPLC delivery system, a 2475 multi lambda fluorescence detector (Waters).  A Luna™ 
C8 (50 × 2 mm, 3 μm) column connected to a guard cartridge with 2.0 to 3.0 mm internal 
diameters (Phenomenex) was used for all the separations. The reagent is pumped by a 
reagent manager (Waters). The DiA solution and the liquid eluting from the column are 
merged through a metal mixing tee and delivered to the detector. The data is collected 
and processed with the Empower™ software suite (Waters). In the LC-ESI/MS/MS 
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control method, LPAs were separated in an Accela UPLC system (Thermo Fisher, San 
Jose, CA) and detected via an LTQ-Orbitrap XL Discovery instrument (San Jose, CA, 
USA), equipped with an ESI ion max source. 
2.2.3 Extraction and LPA enrichment procedure for plasma samples 
Human plasma (0.8 mL) is mixed with 4 mL MeOH: CHCl3 2:1, and vortexed at 
2000 rpm for 30 s. The mixture is incubated at 4 ºC for 20 min, warmed to rt and 
centrifuged at 2000 rpm for 10 min. The supernatant is decanted from the precipitated 
proteins and extracted with 2 mL phosphate buffer saline (10 mM, pH 7.4) and vortexed 
at 2000 rpm for 30 s. The aqueous phase containing the LPAs is washed two times with 
1.33 mL CHCl3 to remove the remaining neutral lipids. The aqueous layer is acidified to 
pH 2.0 with concentrated H3PO4 to protonate the LPAs to convert them to their neutral 
form.51  An SPE cartridge is preconditioned with 6 mL MeOH, followed by 3 mL H2O. 
The acidified LPAs solution is loaded onto the cartridge and rinsed with 3 mL H2O 
followed by 1 mL CHCl3. The SPE cartridge is dried by applying an N2 stream, and 
LPAs are eluted with 4 mL of MeOH. The solvent is evaporated and the residue is 
reconstituted in 0.16 mL MeOH: H2O 9:1. 
2.2.4 Fluorescence determination of linearity and dynamic range for DiA: LPA 18:0 
model system 
Stock solutions of varying concentrations (0–150 µM) of LPA (18:0) were 
prepared in a mixture of MeOH–CHCl3 1:1. To avoid aggregation of the lipids, films of 
each sample were prepared by evaporation under an Ar stream, and the films 
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reconstituted in MeOH. Choline chloride (final concentration 6.4 mM) 52  was added 
before mixing with DiA (final concentration 2.67 µM) aqueous solution. 
2.2.5 HPLC post-column procedure for plasma analysis 
Samples (20 µL) are injected and eluted with a 16:5 mixture of MeOH-phosphate 
buffer (50 mM, pH 2.5) through a Luna C-8 (50 × 2 mm, 3 µm) column equipped with a 
guard column. The end of the column is connected to a mixing tee allowing contact with 
the post-column reagent solution (DiA, 10 µM). The flow rate of the mobile phase is set 
to 0.32 mL min-1 and 0.62 mL min-1 for the post-column reagent. The entire procedure is 
performed at room temperature. 
2.2.6 LC-ESI/MS/MS validation procedure for plasma analysis 
Chromatography was performed on a Luna C-8 (50 × 2 mm, 3 µm) column at 40 
ºC with an injection volume of 10 µL. The mobile phase MeOH–HCOOH (10 mM, pH 
2.5) 9:1 was delivered at a flow rate of 0.4 mL min-1. Ions were created in negative ion 
mode by setting the sprayer voltage at 3.0 kV and the capillary temperature at 300 ºC. 
2.3 Results and discussion 
2.3.1 Selection of the post-column reagent 
Typically, fluorescent probes used for the post-column detection of phospholipids 
rely on the formation of aggregated non-fluorescent pi-stacked assemblies. These 
assemblies are disrupted, upon interaction with phospholipids, thereby restoring probe 
fluorescence. Examples of phosphoplipid-interacting probes include 2,5-bis-2-(5-tert-
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butyl)benzoxazolylthiophene (BBOT), 1,6-diphenyl-1,3,5-hexatriene (DPH) and 4-(4-
dimethylaminostyryl)-1-hexadecylpyridinium (DSHP). 37 53-55 56 Structures of BBOT, 
DPH and DSHP are shown in Figure They are mainly used for the detection and 
quantification of triglycerides, ceramides, glycosphingolipids and phosphatidylcholines. 
In our hands, we found that both BBOT and DPH did not produce usable fluorescence 
emission enhancement in the presence of lysophosphatidic acids. Other fluorescent 
probes with amphiphilic properties were evaluated. 10-N-Nonyl acridine orange (NAO) 
has been used in the analysis of certain phospholipids such as cardiolipin (CL); 36 57, 58 
however, it did not produce a useful spectral response in LPA-containing solutions. The 
amphiphilic cyanine-type probe 4-(4-(dihexadecylamino)styryl)- N-methylpyridinium 
iodide (DiA) afforded the most promising results for LPA detection. These results can be 
explained considering the structural characteristics of BBOT and DPH, which are 
essentially non-polar probes, while LPA (and PA) are amphiphilic charged molecules. 
Better binding is expected to occur with DiA through electrostatic interactions between 
the quaternary ammonium moiety and the phosphate group of LPA.  Probe structures 
including DiA, DSHP, BBOT, DPH and NAO are shown in Figure 2.1. 
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Figure 2.1  Structures of probe candidates including DiA, DPH, DSHP, NAO and BBOT. 
  16
 
Figure 2.2  Absorption spectra (top) and fluorescence spectra (bottom) of 3 μM aqueous solutions 
of DiA alone (dashed lines) and in the presence of 10 μM LPA 18:0 (solid lines). 
Excitation/emisson wavelengths: 470/590 nm. 
 
An aqueous probe solution (3 µM) responds to the addition of 10 µM LPA 18:0 
with a 40% increase at 445 nm in absorption. Importantly, the probe exhibits weak 
fluorescence in the absence of LPA and a 700% increase in fluorescence emission upon 
addition of 10 µM LPA. (Figure 2.2) It is notable that a relatively small increase in the 
extinction coefficient of DiA upon addition of LPA produced a dramatic increase in the 
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fluorescence response. It is known that DiA exhibits minimal fluorescence in aqueous 
solution, yet the fluorescence emission has been found to increase greatly when bound to 
membrane environments. 59 It follows that LPA bound DiA would exhibit similar 
increases in fluorescence. 
2.3.2 Probe concentration and flow rate 
Solutions of DiA with concentrations ranging from 3 to 20 µM were evaluated for 
LPA screening. The 10 µM DiA solution exhibited the best signal-to-noise (S/N) ratio, 
with a relatively low fluorescence background. The optimal reagent flow rate for post-
column detection was found to be 0.62 mL min-1. Higher flow rates resulted in relatively 
better signal to noise ratios, however, a trade-off was dilution of the sample. To best 
prepare a DiA solution in H2O, we found that DiA should be pre-dissolved in a small 
amount of acetone (1% of H2O volume). 
2.3.3 Mobile phase composition, pH and effects of other additives 
Common solvent mixtures (MeOH–H2O, MeCN–H2O) used for reversed-phase 
chromatography did not enable resolution of the targeted individual LPA subspecies. 
Subspecies separation was dependent on buffer pH and concentration. Of the buffer 
systems evaluated, phosphate afforded optimal separation and peak shapes. Optimal 
resolution was achieved using MeOH–50 mM phosphate buffer, pH 2.5 in a ratio 16/5. 
The parameters characterizing the chromatographic system for optimal separation of 
LPAs are reported in Table 2.1-2.3. 
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Table 2.1  Effect of column length on the resolution (Rs) and theoretical plates (N) for the separation of LPAs.
a 
 LPA 14:0  LPA 20:4  LPA 16:0  LPA 18:1  LPA 17:0  LPA 18:0 
column length 
(mm) 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
100b 
 
312  
(4.44) 
2.31 
 
192 
(5.56) 
1.35 
 
1715 
(6.53) 
NA 
 
NA 
(7.89) 
NA 
 
2712 
(8.71) 
7.74 
 
3001 
(11.87) 
50c 
 
1280 
(3.83) 
4.40 
 
1486 
(4.72) 
3.52 
 
1917 
(5.44) 
4.30 
 
1748 
(6.61) 
2.57 
 
3416 
(7.32) 
10.04 
 
4361 
(10.50) 
 
aLPA concentration: 80 μM; mobile phase: 4/1 MeOH/50 mM pH 3.0 phosphate buffer; injection volume: 5 μL.   
bDiscovery Bio wide pore (Supelco), C-8, 3 μm, 2.1 mm diameter.  Flow rate: 0.20 mL/min. 
cLuna (Phenomenex), C-8, 3 μm, 2.0 mm diameter. Flow rate: 0.27 mL/min. 
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Table 2.2  Effect of pH on the resolution (Rs) and theoretical plates (N) for the separation of LPAs.
a 
 LPA 14:0  LPA 20:4  LPA 16:0  LPA 18:1  LPA 17:0  LPA 18:0 
pH 
 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
3.0 
 
996 
(3.01) 
7.93 
 
1302 
(4.69) 
3.14 
 
1040 
(5.59) 
4.22 
 
1860 
(6.92) 
1.65 
 
397 
(7.78) 
5.66 
 
2176 
(11.12) 
2.5 
 
1331 
(3.16) 
9.71 
 
2000 
(4.85) 
3.41 
 
1862 
(5.61) 
4.82 
 
1625 
(6.99) 
2.56 
 
1630 
(7.88) 
7.57 
 
1828 
(11.21) 
 
aLPA concentration is 5 μM; column: Luna C-8 50 × 2.0 mm; mobile phase: 7/2 MeOH/50 mM phosphate buffer; flowrate: 0.27 
mL/min. Injection volume: 20 μL. 
 
Table 2.3  Resolution (Rs) and theoretical plates (N) for the final optimal conditions. The column size is 50×2.0 mm.
a 
 LPA 14:0  LPA 20:4  LPA 16:0  LPA 18:1  LPA 17:0  LPA 18:0 
 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
Rs 
 
N 
(RT, min) 
 
848 
(3.96) 
6.25 
 
1149 
(5.76) 
3.75 
 
2531 
(6.84) 
5.71 
 
2105 
(8.58) 
2.65 
 
1278 
(9.72) 
8.28 
 
2635 
(13.96) 
 
aLPA concentration is 10 μM; mobile phase: 16/5 MeOH/50 mM phosphate buffer; flowrate: 0.32 mL/min. Injection volume: 20 μL. 
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2.3.4 Separation conditions 
Of the reversed phase columns evaluated, the best results were obtained with a   
C-8 column with a particle size of 3 µm. A 100 × 2.1 mm column enabled separation of 
all LPAs but caused excessive back-pressure, and limited optimization of the 
composition/flow rate of mobile phase. A shorter 50 × 2 mm column enabled increased 
flow rate affording sharper peaks and significantly reduced analysis time (~ 15 min). The 
parameters characterizing the chromatographic system for optimal separation of LPAs are 
reported in Table 2.1–2.3. Minimizing the length of the tubing between the HPLC 
column and post-column mixing tee is also critical for maximizing peak-to-peak 
resolution and limits of detection. 
2.3.5 Detection parameters 
Determination of the optimum excitation and emission wavelengths for the HPLC 
fluorescence detection system were performed as follows. The 3-D scanning mode in a 
Waters 2475 fluorescence detector allowed us to establish the optimal excitation and 
emission wavelengths that resulted in the highest signals and best peak shapes based on 
the wavelength dependence of the excitation source and PMT detector employed by the 
Waters 2475 fluorescence detection system. The largest LPA induced fluorescence 
emission enhancement was observed to be near 570 nm when run in emission scanning 
mode with excitation at 470 nm chosen based upon the excitation spectra in Figure 2.2. 
The detector gain was set to 100. Subsequently, the acquisition was set to excitation 
scanning mode (330–530 nm) keeping the emission wavelength constant (570 nm) 
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allowing collection of an excitation spectrum. The peak excitation wavelength resulting 
in the greatest fluorescence enhancement was determined to be 450 nm. Consistent with 
Figure 2.2, the post-column fluorescence response to LPA was much greater than 
absorption. Fixed excitation and emission wavelengths of 450 and 570 nm, respectively 
were used in all analyses and presented in all subsequent chromatograms. Figure 2.3 
shows a representative HPLC trace using the optimized conditions for the separation of 
LPA 14:0, 16:0, 17:0, 18:0, 18:1 and 20:4. 
 
 
Figure 2.3 HPLC trace of a LPA mixture (10 μM LPA 14:0, 16:0, 18:0, 18:1, 20:4 and 20 μM 
LPA 17:0). Chromatographic conditions: column: Luna™ C8, 3 μm, 50 × 2.0 mm; 
mobile phase: MeOH: phosphate buffer (50 mM, pH 2.5) 16:5; flow rate: 0.32 mL/min; 
injection volume: 20 μL; sample concentration: 10 μM in MeOH: H2O 9:1; post-column 
reagent: 10 μM DiA in H2O; reagent flow rate: 0.62 mL/min; excitation/emission 
wavelengths: 450/570 nm. 
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2.3.6 Linearity and dynamic range 
In order to determine the linear response of DiA to the presence of LPA, an initial 
evaluation using LPA (18:0) as a model compound was carried out using direct 
fluorescence spectrophotometry. Emission spectra were collected upon excitation at 470 
nm. As shown in Figure 2.4, the plot of maximum fluorescence emission vs. 
concentration confirms a good linear relationship (R2 = 0.994) between the fluorescence 
intensity and LPA (18:0) concentrations ranging from 1 to 16 μM.   
 
 
Figure 2.4  Emission spectra and calibration curve (inset) of 2.67 μM DiA upon titration with 
LPA (18:0). 
 
Based on the above results, we anticipated that a similar linear response would be 
obtained for the individual LPAs after reversed phase HPLC separation. After 
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optimization of separation and detection conditions as described above, mixtures of LPAs 
with concentrations ranging from 0.5 – 40 μM were evaluated.  
All LPAs showed a linear response in the 0.5 – 25 μM concentration range, 
although LPA 14:0, LPA 18:0 and LPA 18:1 exhibit linearity up to 40 μM.  LPA (17:0), 
a non-natural LPA, was added to these mixtures as an internal standard for further 
quantification.  Figure 2.5 shows calibration curves for the individual LPA species 
evaluated in this study.  Acceptable correlation factors (R2) were obtained for all LPA 
subspecies. The limit of detection (LOD) for each was determined as the amount of 
analyte that corresponds to three times the signal of the background noise. Data from 
calibration curves are shown in Table 2.4. 
 
Figure 2.5 Calibration curves of specific LPA subspecies obtained by HPLC-post column 
fluorescence detection. The area ratio is the peak area of individual LPAs divided by the 
peak area of the internal standard (LPA 17:0).  Data points represent the average of 4 
runs. 
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Table 2.4  Data obtained from calibration curves for LPA species via the HPLC post-column method. 
LPA species 
 
Retention  time 
(min) 
 
Linear range 
(μM) 
R2 
 
LOD 
(μM) 
14:0 3.50 0-40 0.9962 0.147 
20:4 5.56 0-25 0.9962 0.161 
16:0 6.64 0-25 0.9963 0.173 
18:1 8.35 0-40 0.9949 0.074 
18:0 13.75 0-40 0.9943 0.272 
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2.3.7 Quantification of LPAs in human plasma 
Biological concentrations of phospholipids in human plasma are higher than 3 
mM. 33 Among the several classes of phospholipids that are present in human plasma, 
LPAs represent a relatively very small fraction, and reported concentrations of total LPA 
vary.  A generally reported range is 1-5 μM.34 This imposes a challenge for the selective 
isolation/enrichment of these analytes.  Solid phase extraction (SPE) is a common 
method for the removal of potential interferences from biological samples and has been 
used for the isolation and enrichment of the different classes of phospholipids.60-62 
Typical SPE materials include normal phase (e.g. silica), reversed phase (C4, C8 or C18), 
ionic exchange and hybrid solid supports. The SPE enrichment procedure developed 
herein specifically for LPAs increases their concentration 5-fold. Several solid supports 
were initially evaluated in control mixtures containing LPA 14:0, 16:0, 17:0, 18:0, 18:1 
and 20:4.  Three different commercial reversed phase C8 SPE cartridges, including 
Waters (Sep-pak™ Plus C-8, 200 mg, 37-55 μm), Supelco (Discovery™ DSC-8, 3 mL, 
500 mg, 50 μm) and Waters (OASIS™ HLB 3 mL, 60 mg, 30 μm) were evaluated.  The 
OASIS™ HLB proved optimal in terms of LPA recoveries (93-103%). As part of the 
method development, a liquid-liquid extraction prior to the SPE procedure was used to 
aid in removing relatively abundant and potentially interfering phospholipids. Typical 
procedures for lysophospholipids reported in the literature involve acidification of plasma 
prior to a liquid-liquid extraction.15, 63 In our hands, this procedure gave very low LPA 
recoveries.  We determined that pH control was critical to achieve the selective removal 
of interferences.  At physiological pH, LPAs are negatively charged.51 Thus, performing 
the liquid-liquid extraction at pH 7.4 removes neutral phospholipids (e.g. LPC, LPS, etc.).  
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The best recoveries were obtained when samples were loaded onto the SPE cartridge at 
pH 2.0. Selective elution of LPAs from the SPE cartridges was achieved using MeOH. 
This removes relatively hydrophobic species (e.g. phosphatidic acids).  Table 2.5 shows 
the recoveries obtained for LPA control samples.  In general, the recoveries are in the 74-
94% range.  In addition, we evaluated the effect of other phospholipids that have been 
identified to be present in human plasma and can result in potential false positives for 
LPAs.  It is known that phospholipids are prone to either chemical or enzymatic 
hydrolysis. Phosphatidic acids (PAs) can be hydrolyzed enzymatically during sample 
storage, producing the corresponding LPAs, resulting in false positive LPA readings.  
Due to the acidic conditions in which the LPA solid phase extraction is carried out, we 
performed control experiments to investigate PA hydrolysis consisting in submitting PA 
standards to the whole extraction procedure.  The resulting chromatograms did not show 
any signal within 1 hour, hence, none of PA 14:0, 16:0, 18:0 or 18:1 are hydrolyzed 
under the conditions used for the SPE-based LPA enrichment reported herein. 
Phosphatidylcholines (PCs) represent the major components of biological membranes 
and are also prone to hydrolysis producing the corresponding LPCs or PAs. Evaluation of 
the hydrolysis of PC in the same fashion as with PA resulted in the absence of any 
hydrolysis product confirming that PC or its hydrolysis products do not interfere in our 
sample protocol. 
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Table 2.5  Recoveries of individual LPA species after SPE enrichment. 
 
LPA   species 
Measured by HPLC- post column (n = 3) Measured by LC- ESI/MS/MS (n =3) 
Recovery (%) σ (%) Recovery (%) σ (%) 
14:0 93.5 4.8 93.7 2.9 
20:4 73.8 4.3 76.6 1.2 
16:0 94.2 5.4 95.7 4.6 
18:1 76.9 4.9 77.6 1.7 
17:0 85.1 3.8 85.0 4.6 
18:0 76.9 4.4 73.1 2.4 
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An LC/MS full scan in both negative and positive modes was also used to 
determine the presence of non-LPA phospholipids in plasma to confirm the effectiveness 
of the new sample preparation extraction steps. A control mixture of 22 phospholipids 
was initially tested, and all lipids were detectable in negative and/or positive mode. Mass 
spectra are shown in Figure 2.6-2.9.  A plasma extract was tested using the same method. 
Results were compared to the LIPID MAPS Structure Database (LMSD).64 No 
potentially interfering lipids found in the database were detected in negative mode. 
Limited amounts of LPC 16:0 were detected in positive mode. To further determine the 
extent of the interference from LPC, an LC-ESI/MS/MS method was used to detect LPC 
subspecies. The concentration was estimated to be 0.06, 0.01 and 0.05 μM for LPC 16:0, 
LPC 18:0 and LPC 18:1 respectively. These concentrations represent less than 0.1 % of 
the total LPCs in human plasma,35, 65 thus LPC interference is not significant in our 
method. 
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Figure 2.6  Mass spectra of phospholipids mixture in negative mode 
 
Figure 2.7  Mass spectra of phospholipids mixture in positive mode 
LPA 14:0
LPA 18:1
LPA 20:4
LPA 17:0
LPA 18:0
PS 16:0
PA 16:0
LPE 18:1
PS 18:1
PA 18:1
PA 14:0
LPA 16:0
PE 18:1LPE 16:0
LPS 18:1
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Figure 2.8  Mass spectra of plasma extract in negative mode 
 
Figure 2.9  Mass spectra of plasma extract in positive mode 
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2.3.8 Method validation via LC-ESI/MS/MS 
Mixtures of LPAs with concentrations ranging from 0.5 – 40 μM were evaluated 
using the LC-ESI/MS/MS method. We found a linear response for all the LPAs 
throughout this range. To compare to the new HPLC post-column method, we selected a 
working concentration range of 0.5 – 25 μM.  LPA (17:0) was also used as an internal 
standard.  Figure 2.10 shows calibration curves for the individual LPA species evaluated 
with the LC-ESI/MS/MS method.  Acceptable correlation factors (R2) were obtained for 
all the LPAs (Table 2.5). The limit of detection (LOD) for each LPA species was 
determined as the amount of analyte that corresponds to three times the signal of the 
background noise. 
 
Figure 2.10  Calibration curves of LPAs using the LC-ESI/MS/MS method. The area ratio is the 
peak area of individual LPAs divided by the peak area of the internal standard (LPA 
17:0). 
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Table 2.6  Statistical values obtained for the individual LPA species in the LC-ESI/MS/MS 
method (n = 3). 
LPA species Retention time 
(min) 
Linear range 
(μM) 
R2 LOD 
(μM) 
14:0 6.30 0-40 0.9991 0.0067 
20:4 7.55 0-40 0.9990 0.0099 
16:0 8.29 0-40 0.9998 0.0123 
18:1 9.10 0-40 0.9993 0.0066 
18:0 11.22 0-40 0.9991 0.0156 
 
Native LPA concentrations were determined in blind human plasma samples from 
five different donors using both the MS and the optical methods. In addition, to further 
evaluate other potential matrix interferences, these plasma samples were also spiked with 
0.5 μM of each LPA species.  Data from the samples collected from all five donors is 
presented in Table 2.7-2.11. In each experiment, 800 μL of human plasma was used. All 
samples were prepared and analyzed in triplicate. Result shows that LPAs concentrations 
determined by the LC-ESI/MS/MS and HPLC optical post-column techniques are in 
close agreement. Experimental recoveries were mostly higher in the HPLC-post column 
method. Representative HPLC traces are shown in Figure 2.11 and Figure 2.12. 
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Table 2.7  Results for LPA analysis in human plasma (donor A) using the HPLC post-column fluorescence and LC-ESI/MS/MS methods. 
 
non-spiked (μM)  
average, σ 
spiked with 0.5 µM LPA (μM)  
average, σ 
Recovery (%) 
 HPLC post-column LC-ESI/MS/MS HPLC post-column LC-ESI/MS/MS HPLC post-column LC-ESI/MS/MS 
LPA 14:0 0.90 (0.01) 0.92 (0.01) 1.31 (0.09) 1.33 (0.05) 82 82 
LPA 20:4 0.63 (0.02) 0.64 (0.03) 1.09 (0.05) 1.06 (0.03) 94 84 
LPA 16:0 0.76 (0.03) 0.74 (0.01) 1.19 (0.09) 1.19 (0.01) 86 90 
LPA 18:1 0.68 (0.01) 0.65 (0.02) 1.18 (0.01) 1.10 (0.03) 98 90 
LPA 18:0 0.56 (0.02) 0.60 (0.01) 1.06 (0.03) 1.05 (0.01) 100 88 
Total LPA 3.5 3(0.03) 3.56 (0.02) 5.83 (0.22) 5.73 (0.11) 92 87 
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Table 2.8  Results for LPA analysis in human plasma (donor B) using the HPLC post-column fluorescence and LC-ESI/MS/MS methods. 
 
non-spiked (μM)  
average, σ 
spiked with 0.5 µM LPA (μM)  
average, σ 
Recovery (%) 
 HPLC post-column LC-ESI/MS/MS HPLC post-column LC-ESI/MS/MS HPLC post-column LC-ESI/MS/MS 
LPA 14:0 0.97(0.03) 1.03(0.01) 1.43(0.04) 1.45(0.03) 94 82 
LPA 20:4 0.98(0.01) 0.94(0.01) 1.41(0.02) 1.43(0.01) 86 100 
LPA 16:0 0.96(0.02) 1.04(0.02) 1.45(0.03) 1.60(0.03) 98 112 
LPA 18:1 1.05(0.00) 1.03(0.02) 1.47(0.02) 1.55(0.02) 84 102 
LPA 18:0 0.99(0.01) 0.93(0.01) 1.56(0.04) 1.47(0.01) 114 110 
Total LPA 4.96(0.04) 4.97(0.04) 7.33(0.01) 7.50(0.08) 95 101 
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Table 2.9  Results for LPA analysis in human plasma (donor C) using the HPLC post-column fluorescence and LC-ESI/MS/MS methods. 
 
non-spiked (μM)  
average, σ 
spiked with 0.5 µM LPA (μM)  
average, σ 
Recovery (%) 
 HPLC post-column LC-ESI/MS/MS HPLC post-column LC-ESI/MS/MS HPLC post-column LC-ESI/MS/MS 
LPA 14:0 0.76(0.01) 0.68(0.02) 1.25(0.02) 1.21(0.04) 98 106 
LPA 20:4 0.21(0.02) 0.27(0.02) 0.64(0.01) 0.67(0.05) 84 80 
LPA 16:0 0.55(0.01) 0.42(0.04) 1.05(0.05) 0.97(0.04) 100 112 
LPA 18:1 0.37(0.01) 0.32(0.01) 0.96(0.05) 0.79(0.06) 120 96 
LPA 18:0 0.29(0.03) 0.23(0.01) 0.79(0.01) 0.79(0.02) 102 112 
Total LPA 2.18(0.02) 1.91(0.09) 4.69(0.08) 4.44(0.12) 100 101 
 
  
3
6
Table 2.10  Results for LPA analysis in human plasma (donor D) using the HPLC post-column fluorescence and LC-ESI/MS/MS methods. 
 
non-spiked (μM)  
average, σ 
spiked with 0.5 µM LPA (μM)  
average, σ 
Recovery (%) 
 HPLC post-column LC-ESI/MS/MS HPLC post-column LC-ESI/MS/MS HPLC post-column LC-ESI/MS/MS 
LPA 14:0 0.24(0.00) 0.23(0.01) 0.65(0.02) 0.68(0.02) 82 92 
LPA 20:4 0.26(0.01) 0.28(0.01) 0.67(0.01) 0.65(0.04) 82 74 
LPA 16:0 0.45(0.03) 0.43(0.01) 0.88(0.02) 0.83(0.04) 88 80 
LPA 18:1 0.30(0.02) 0.38(0.01) 0.87(0.02) 0.85(0.03) 114 94 
LPA 18:0 0.33(0.02) 0.31(0.00) 0.85(0.02) 0.82(0.01) 104 102 
Total LPA 1.57(0.03) 1.63(0.03) 3.91(0.03) 3.83(0.12) 94 88 
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Table 2.11  Results for LPA analysis in human plasma (donor E) using the HPLC post-column fluorescence and LC-ESI/MS/MS methods. 
 
non-spiked (μM)  
average, σ 
spiked with 0.5 µM LPA (μM)  
average, σ 
Recovery (%) 
 HPLC post-column LC-ESI/MS/MS HPLC post-column LC-ESI/MS/MS HPLC post-column LC-ESI/MS/MS 
LPA 14:0 0.17(0.00) 0.18(0.01) 0.61(0.02) 0.60(0.00) 86 84 
LPA 20:4 0.20(0.02) 0.23(0.01) 0.75(0.01) 0.77(0.01) 110 110 
LPA 16:0 0.29(0.00) 0.28(0.02) 0.71(0.00) 0.76(0.01) 84 96 
LPA 18:1 0.53(0.01) 0.47(0.02) 0.97(0.02) 1.03(0.00) 90 112 
LPA 18:0 0.33(0.00) 0.30(0.01) 0.84(0.01) 0.89(0.00) 102 118 
Total LPA 1.52(0.02) 1.45(0.05) 3.88(0.04) 4.06(0.01) 94 104 
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Figure 2.11  Chromatograms of a mixture containing 10 µM of each LPA species and LPAs 
isolated from human plasma (donor A) using the post-column detection method. 
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Figure 2.12  LC-ESI/MS/MS traces of a 10 μM standard mixture of LPAs. Column: Luna™ C8 
(50 × 2 mm, 3 μm) at 40 ºC. Injection volume: 10 μL. Mobile phase: 9:1 
MeOH:aqueous HCOOH (pH 2.5) at a flow rate of 0.4 mL/min.  Parent and daughter 
ions were detected in the negative ion mode, sprayer voltage; 3.0 kV, capillary 
temperature at 300 ºC. 
2.4 Conclusion 
The optimized method for isolation and enrichment of LPA subspecies over other 
related phospholipids developed herein  affords the five major LPAs (LPA 14:0, 16:0, 
18:0, 18:1 and 20:4) with essentially no other potentially interfering phospholipids. Using 
this enriched mixture during analysis can eliminate matrix related errors caused by the 
0
100
0
100
0
100
0
100
0
100
0
100
0
100
0 2 4 6 8 10 12 14 16
LPA 14:0
LPA 20:4
LPA 16:0
LPA 18:1
LPA 17:0
LPA 18:0
Time (min)
R
e
la
ti
v
e
 A
b
u
n
d
a
n
ce
  40
presence of other phospholipids which can potentially generate LPAs upon hydrolysis. 
The HPLC separation of the individual LPA subspecies reported herein is relatively rapid 
(15 min), and non-destructive optical detection simplifies the selection of detection 
instrumentation.  Optical detection was validated using ESI/MS/MS detection, for which 
the optimized sample enrichment procedure reduced or completely eliminated ionization 
suppression effects that have been reported to complicate the measurement. 
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Chapter 3 Clinical study of LPA levels in ovarian cancer patients 
 
3.1 Introduction 
Xu et al. 66 first reported that LPA levels were elevated in ovarian cancer patients 
and LPA may be a biomarker of ovarian cancer, especially for early stages.  Many other 
groups have reported clinical studies supporting LPA as a diagnostic biomarker of 
ovarian cancer. 17, 67 For example, Sedlakova et al. 19, 68 found that LPA levels in ovarian 
cancer patients plasma were elevated by ~140% thus LPA could be useful as diagnostic 
marker for ovarian cancer.   
However, Baker et al. 20 found that neither individual LPA species nor total LPA 
levels in plasma of ovarian cancer patients was significantly different than a healthy 
control group. More recently, Lu et al. 69 studied  more than 600 patients including 
healthy women and those with ovarian cancer. The results showed that measurement of 
total LPA levels in serum was highly accurate and sensitive towards the diagnosis of 
ovarian cancer. Even among studies that showed plasma LPA levels were elevated in 
ovarian cancer patients, the total LPA concentrations reported varied widely, from 2.57 to 
43.2 µM for ovarian cancer patients. 17, 19, 34, 66  To help understand this controversial 
issue, we performed a clinical study of LPA levels in ovarian cancer patients using the 
method developed by our group, which is described in Chapter 2, in collaboration with 
Women and Infants Hospital of Brown University Medical School in Rhode Island. 
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3.2 Experimental 
A total of 183 patient plasma and serum blind samples, including both healthy and 
ovarian cancer patients, were collected at the Women and Infants Hospital of Brown 
University Medical School in Rhode Island. Five subspecies of LPA including LPA 14:0, 
LPA 16:0, LPA 18:0, LPA 18:1 and LPA 20:4 were extracted, enriched with a liquid-
liquid extraction followed by a solid phase extraction method as described in Chapter 2.  
The concentrations of each LPA subspecies were determined with the HPLC post-column 
fluorescence detection method we developed. 70  
3.3 Results and discussion 
Plasma LPA levels in all patients ranges (n = 183): LPA 14:0 (0.109-2.609 
µmol/L), LPA 20:4 (0-1.953 µmol/L), LPA 16:0 (0.229-9.497 µmol/L), LPA 18:1 (0-
0.632 µmol/L), LPA 18:0 (0-2.466 µmol/L), total LPA (0.519- 13.925 µmol/L). Serum 
LPA levels in all patients ranges (n = 183): LPA 14:0 (0-2.649 µmol/L), LPA 20:4 (0-
3.156 µmol/L), LPA 16:0 (0-11.853 µmol/L), LPA 18:1 (0- 0.729 µmol/L), LPA 18:0 (0-
2.543 µmol/L), total LPA (0-15.109 µmol/L).  
We noticed most of the plasma and serum samples are yellow and white. 
However, some samples showed different colors, such as orange and red. These colors 
might be from the residual red blood cells from sample processing.  
All samples were quantified in 3 runs or 2 runs depending on the sample volume.  
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Plasma and serum concentrations of LPA species and total LPA of all patients are 
shown in Figure 3.1-3.6. Statistical analysis of the data for determination of the relevance 
of LPAs as an ovarian cancer biomarker is currently underway by collaborators. 
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Figure 3.1  LPA 14:0 concentrations in plasma and serum samples of 183 patients.  
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Figure 3.2  LPA 20:4 concentrations in plasma and serum samples of 183 patients.  
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Figure 3.3  LPA 16:0 concentrations in plasma and serum samples of 183 patients.  
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Figure 3.4  LPA 18:1 concentrations in plasma and serum samples of 183 patients.  
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Figure 3.5  LPA 18:0 concentrations in plasma and serum samples of 183 patients. 
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Figure 3.6  Total LPA concentrations in plasma and serum samples of 183 patients. 
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Chapter 4 Molecular imprinted polymer synthesis and evaluation  
 
4.1 Introduction 
A wide variety of methods for LPA sample preparation have been developed. 
Liquid-liquid extraction (LLE) is the most common methodology for LPA enrichment 
from biological samples. The LLE method developed by Bligh and Dyer 50 has been 
modified and used in many studies. These modified methods that require one or two steps 
are easy and fast. 3 71 42 49 However, they can also be less than ideal because abundant 
potential interferences, such as lysophosphotidyl choline (LPC), can be co-extracted with 
LPA and affect LPA quantifications. 
For example, Zhao et al. found that lysophosphatidylcholine (LPC) and 
lysophosphatidylserine (LPS) artificially generate LPA signals in electrospray ionization 
tandem mass spectrometry (ESI-MS/MS) at the ion source via loss of the head group. 72 
This fact may highly effect the quantification, since the biological concentration of total 
LPC is about 300 µM, which is two orders of magnitude higher than LPA (< 5 µM) in 
healthy people. 67, 73 Meanwhile, phospholipids such as glycerophosphocholines and 
lysophosphatidylcholines, can cause matrix effects that suppress or enhance MS 
ionization and also shift HPLC retention times and elevate baselines. 44, 46, 74 These 
factors can hamper the accuracy and reproducibility of the quantification of LPA in LC-
MS. Other quantification methods besides LC-MS may also be affected by the presence 
of interfering phospholipids in LPA samples because of the structural similarities 
between LPA and other phospholipids. For example, phosphatidic acid (PA) has the same 
head group as LPA; lysophosphatidylethanolamine (LPE), lysophosphatidylserine (LPS) 
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and LPC all have the same or similar length of alkyl chains as LPA. Thus, if the detection 
is based on phosphate group binding or deaggregation of a binding group induced by the 
alkyl chain of LPA, the phospholipids that co-extract with LPA would interfere. Thus, 
removal of interferences is critical for an accurate quantification of LPA.  
Our group has reported a method for LPA extraction and enrichment by using 
LLE followed by a solid phase extraction (SPE) 70. With that method, LPA could be 
extracted with a high recovery and purity level. To improve the efficiency of the sample 
preparation and reduce the labor intensity and operational difficulties caused by LLE, we 
eliminated the LLE step by using a synthetic MIP as the stationary phase in SPE. 
Compared to LLE, SPE has advantages including high recoveries without partition issues, 
and it is less labor intensive and time consuming, and is potentially automatable.  
Molecularly imprinted polymers (MIPs) are highly cross-linked polymers that can 
be used as artificial receptors for specific molecules. 75-77 MIPs have been mostly used in 
chromatography 78-80, electrophoresis 81, 82, solid phase extraction 83, chemical sensing 84-
88 and catalysis 89 90. New applications of MIPs also include drug delivery 91 92 93 94, 
crystallization 95-98, synthetic antibodies 99, 100 and cell culturing 101-103. To synthesize 
MIPs, the template and functional monomers are bound covalently or non-covalently 
before copolymerized with the presence of a high concentration of crosslinking 
monomers. After the removal of the template, a polymer with cavities and binding sites is 
formed and can be used to bind target molecules selectively. MIPs have many advantages 
as a material for the extraction of specific compounds. MIPs can be customized and 
modified simply by varying the selection and composition of the functional and 
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crosslinking monomers. Functional monomers may not only be selected from the ones 
that are commercially available 104, but also designed and synthesized for target 
compounds, which allows the possibility of MIP being highly selective. The synthesis is 
also relatively easy and inexpensive. 
Compared to using only commercially available functional monomers such as 
methacrylic acid (MAA), multifunctional monomers that contain more than one 
functional group can bind with a higher affinity to the template molecule and with 
reduced nonspecific binding to other molecules. 87 105 106 
 
 
Figure 4.1  Energy-minimized model of the complex of a tris-urea scaffold and LPA 18:1. 
MIPs with urea moieties as receptors for the phosphate group have been designed 
and synthesized. The N-H groups of urea can bind to phosphates via hydrogen bonding 
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and electrostatic interactions. 107 108 109 However, no prior studies have been reported 
involving specific LPA analysis. Figure 4.1 shows an energy-minimized model of a 1:1 
complex of a tris-urea scaffold and LPA using molecular mechanics and Gasteiger-
Hückel charges. 
In this study, we synthesized an MIP that could be used as the stationary phase in 
an SPE cartridge. The functional monomer selected and synthesized was multifunctional, 
containing three urea groups. Because of the selectivity of this MIP, interfering 
phospholipids could be removed from LPA-containing samples. The elimination of the 
LLE step not only improved recoveries of LPA, but also simplified and shortened the 
protocol. 
4.2 Experimental 
4.2.1 Instruments and materials 
NMR spectra were recorded on ARX-400 Advance Bruker spectrometer. FTIR 
spectra were obtained on a ThermoFisher Nicolet iS10 infrared spectrometer (Thermo 
Scientific, Madison, WI) in reflection geometry using a single bounce diamond 
attenuated total reflectance (ATR) accessory. LPA were separated on a LunaTM C-8 (50 
× 2 mm, 3 µm) column connected to a guard cartridge with 2.0 to 3.0 mm internal 
diameters (Phenomenex) in an Accela UPLC system (Thermo Fisher, San Jose, CA).  MS 
data were collected via an LTQ-Orbitrap XL Discovery instrument (San Jose, CA, USA), 
equipped with an ESI ion max source. SEM image were collected with a CEMN’s Zeiss 
Sigma VP SEM. 
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All phospholipids were purchased from Avanti Polar Lipids (Alabaster, AL, 
USA). Hexadecylphosphonic acid, octadecylphosphonic acid, tris(2- aminoethyl) amine,  
2-isocyanatoethyl methacrylate, methacrylic acid (MAA), ethylene glycol dimethacrylate 
(EGDMA),  and 2,2’-azobisisobutyronitrile (AIBN) were purchased from Sigma- Aldrich 
(USA). EGDMA was purified by distillation in vacuo. Human plasma were collected by 
Lampire Biological Laboratories Inc., from female donors, processed to obtain platelet-
free plasma, and frozen at -80 ºC Empty SPE tubes and frits were purchased from Sigma-
Aldrich (USA). HPLC grade methanol, chloroform and water were purchased from VWR 
(USA). 
4.2.2 Synthesis of monomer 1. 
2-Propenoic acid, 2-methyl-, 18-methyl-8-[2-[[[[2-[(2-methyl-1-oxo-2-propen-
1-yl)oxy]ethyl]amino]carbonyl]amino]ethyl]-4,12,17-trioxo-16-oxa-3,5,8,11,13-
pentaazanonadec-18-en-1-yl ester was synthesized as described in literature110   Tris(2- 
aminoethyl) amine (2.2 g, 15.04 mmol) was dissolved in 110 mL dichloromethane and 
cooled to 0 ºC before 2-isocyanatoethyl methacrylate was added in dropwise. The 
mixture was stirred at room temperature for 4 h. The solvent was evaporated and dried 
under vaccum. The yield of the product was 9.2 g (100%). 1H-NMR data was in 
agreement with literature. 1H NMR (400 MHz, CDCl3): δ 6.09 (s, 3H), 6.03 (bs, 3H), 
5.80 (bs, 3H), 5.55 (s, 3H), 4.16 (bs, 6H), 3.43 (bs, 6H), 3.12 (bs, 6H), 2.48 (bs, 6H), 1.90 
(s, 9H). 13C NMR (400 MHz, CDCl3): δ 18.40, 38.72, 39.32, 55.36, 64.29, 126.06, 
136.17, 159.45, 167.52. NMR spectra of monomer 1 are shown in Figure 4.2 and 4.3. 
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Figure 4.2  1H-NMR spectrum of monomer 1. 
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Figure 4.3  13C-NMR spectrum of monomer 1. 
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Figure 4.4  1H-NMR spectrum of monomer 2. 
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Figure 4.5  13C-NMR spectrum of monomer 
HNNH
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4.2.3 Synthesis of monomer 2 
1,1'-(1,3-phenylenebis(methylene))bis(3-(4-vinylphenyl)urea) was synthesized 
as described in literature111. A solution of 4-aminostyrene (1.19 g, 10 mmol) in anhydrous 
THF (40 mL) was stirred at room temperature before 1,3-bis(isocyanatemethyl)benzene 
(0.78 mL, 5 mmol) was added under N2. The reaction was stirred overnight to form a 
white precipitate.  The precipitate was filtered and dried under vacuum to afford the 
product (1.62 g, 76.1%). 1H-NMR (400 MHz, [d6] DMSO): δ 4.30 (d, 4 H), 5.08 (d, 2 H), 
5.67 (d, 2 H), 6.62 (dd, 4 H), 7.15–7.45 (m, 12 H), 8.62 ppm (s, 2 H). 13C-NMR (400 
MHz, [d6] DMSO): δ 42.75, 111.54, 117.58, 125.63, 125.93, 126.59, 128.33, 130.13, 
136.33, 140.26, 140.38, 155.03.  NMR spectra of monomer 2 are shown in Figure 4.4 and 
4.5. 
4.2.4 Synthesis of monomer 3 and 4. 
Vinyl-benzyl-cyclen monomer and Zn (II) vinyl-benzyl-cyclen monomer were 
synthesized as described in literature112.  
1,4,7-tris(tert-butyloxycarbonyl)-1,4,7,10-tetraazacyclododecane. Di-tert-
butyl-dicarbonate (3.59g, 16.43 mmol) solution in CHCl3 (50 mL) was added dropwise to 
the solution of cyclen (1.0 g, 5.80 mmol) and triethylamine(1.81 g, 17.88 mmol) in 
CHCl3 (60 mL) over a 3 hour period. The reaction was stirred for 24 h at rt before the 
solvent was removed under reduced pressure. The crude product was purified via column 
chromatography using silica gel to afford 1,4,7-Tris(tert-butyloxycarbonyl)-1,4,7,10-
tetraazacyclododecane as a colorless solid (1.92 g, 70.1%).  
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1-(4-vinylbenzyl)-4,7,10-tris(tert-butyloxycarbonyl)-1,4,7,10-
tetraazacyclododecane. A solution of 1,4,7-Tris(tert-butyloxycarbonyl)-1,4,7,10-
tetraazacyclo- dodecane (1.7 g, 3.60 mmol), K2CO3 (0.75 g, 5.4 mmol), KI (0.60 g, 3.6 
mmol) , and 4-vinylbenzene chloride (0.82 g, 5.40 mol) in MeCN (60 mL) was stirred at 
70 ºC for 3 h. After the insoluble inorganic salts were removed by filtration, the solvent 
of the filtrate was evaporated under reduced pressure. The crude product was purified by 
column chromatography to provide 1-(4-vinylbenzyl)-4,7,10- tris(tert - butyloxycarbonyl) 
-1,4,7,10-tetraazacyclododecane (1.56 g, 73.6%).  
1-(4-vinylbenzyl)-1,4,7,10-tetraazacyclododecane 2TFA salt. Trifluoroacetic 
acid (12.78 g, 112.1 mmol) is added dropwise to the solution of 1-(4-vinylbenzyl)-4,7,10- 
tris(tert-butyloxycarbonyl)-1,4,7,10-tetraazacyclododecane (1.20 g,  2.04 mmol) in 
CH2Cl2 (130 mL) at 0 ºC. The reaction is stirred overnight at rt.  The solvent was 
evaporated under reduced pressure before toluene (10 mL) was added to the residue and 
evaporated under reduced pressure. The residue was recrystallized from Et2O-EtOH to 
afford 1-(4-Vinylbenzyl)-1,4,7,10-tetraazacyclododecane 2TFA salt (0.98 g, 93.4 %). 
1-(4-vinylbenzyl)-1,4,7,10-tetraazacyclododecane. A solution of 1-(4-
vinylbenzyl)-1,4,7,10-tetraazacyclododecane 2TFA salt (0.8g, 1.55 mmol) in water was 
added to 1M NaOH solution. The aqueous solution was extracted with CHCl3  (50 mL × 
5) and the organic layers were combined and dried over anhydrous Na2SO4. The solvent 
was evaporated under reduced pressure to afford 1-(4-vinylbenzyl)-1,4,7,10-
tetraazacyclododecane (0.44 g, 98.4 %) 1H NMR (400 MHz, CDCl3): δ 0.40-0.80 (m, 16 
H), 1.62 (s, 2H), 3.25 (d, 1H), 3.79 (d, 1H), 4.76 (dd, 1H), 5.30 (d, 2H), 5.44 (d, 2H). 13C 
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NMR (400 MHz, CDCl3): δ 43.69, 44.84, 45.68, 50.28, 57.80, 51.98, 113.46, 125.99, 
129.53, 136.23, 136.36, 138.52. NMR spectra of monomer 3 are shown in Figure 4.6 and 
4.7. 
1-(4-vinylbenzyl)-1,4,7,10-tetraazacyclododecane Zn(NO3)2 salt, 
[ZnL2(NO3)2]. A solution of Zn(NO3)2· 6H2O (0.23 g) in EtOH (4 mL) was added to a 
solution of 1-(4-vinylbenzyl)-1,4,7,10-tetraazacyclododecane (0.20 g, 0.70 mmol) in 
EtOH (0.3 mL) at 60 ºC and stirred for 1 h. The solvent was evaporated under reduced 
pressure and the residue was recrystallized from EtOH-H2O to afford 1-(4-vinylbenzyl)-
1,4,7,10-tetraazacyclododecane Zn (NO3)2 salt, [ZnL2(NO3)2]. (0.23 g, 69.7 %) 
1H NMR 
(400 MHz, CDCl3): δ 0.30-1.1 (m, 16 H), 1.80 (s, 2H), 3.19 (d, 1H), 3.73 (d, 1H), 4.62 
(dd, 1H), 5.17 (d, 2H), 5.34 (d, 2H). 13C NMR (400 MHz, CDCl3): δ 41.69, 41.81, 43.26, 
44.03, 44.15, 48.64, 54.85, 114.47, 125.94, 130.62, 131.22, 135.71, 137.45. NMR spectra 
of monomer 4 are shown in Figure 4.8 and 4.9. 
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Figure 4.6  1H-NMR spectrum of monomer 3. 
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Figure 4.7  13C-NMR spectrum of monomer 3. 
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Figure 4.8  1H-NMR spectrum of monomer 4. 
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Figure 4.9  13C-NMR spectrum of monomer 4. 
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4.2.5 Preparation of imprinted polymer and non-imprinted polymer 
Octadecylphosphonic acid (1.00 g, 2.99 mmol), monomer 1 (1.83 g, 2.99 mmol) 
and methacrylic acid (0.257 g, 2.99 mmol) were dissolved in 37 mL chloroform and 
allowed to stand for 60 min for complex formation. EGDMA (11.9 g, 59.8 mmol) was 
added to the mixture in one portion. The mixture was purged by bubbling nitrogen for 5 
min before and after AIBN (0.245g, 1.49 mmol) was added. Polymerization was carried 
at 55 ºC for 16 h. Polymers were crushed into small pieces before washing with MeOH, 
and extracted using a Soxhlet apparatus with MeOH for 48 h, before grinding and sieving 
to 63-90 µm. 
A non-imprinted polymer was synthesized using the same protocol, but without 
the presence of the template octadecylphosphonic acid. 
4.2.6 1H NMR titrations 
Stock solutions of monomer 1 (40 mM) and octadecylphosphonic acid (20 mM) 
were prepared in CDCl3.  The initial concentration of template was 5 mM and kept 
constant. The monomer concentration was 0, 0.5, 1, 1.5, 2, 3, 4, 5, 7.5, 10, 15 mM, 
respectively. The chemical shifts of proton in urea group and the adjacent methylene 
group were monitored. Titration of methacrylic acid and template octadecylphosphonic 
acid were performed using the same protocol. 
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4.2.7 Job plots for monomers with template 
Stock solutions of functional monomers and templates were the same as in the 1H-
NMR titration experiment. The concentration of the solution was 10 mM and the mole 
ratio of template and monomer were varied from 0/10 to 9/1. The chemical shifts of the 
proton of the urea group and the adjacent methylene group were monitored. A titration of 
the methacrylic acid and octadecylphosphonic acid was performed using the same 
protocol. 
4.2.8 LPA enrichment procedure with MIP  
600 µL human plasma was mixed with 2 mL MeOH-CHCl3 2:1, vortexed at 2000 
rpm for 30 s and incubated at 4 ºC for 20 min. After warming to rt, the mixture was 
centrifuged at 2000 rpm for 10 min. The supernatant was decanted and loaded onto a 
cartridge packed with the non-imprinted polymer (NIP). The cartridge was eluted with 2 
mL 0.05% NH4OH in MeOH. The eluent was acidified to pH 3.0 with concentrated 
formic acid and loaded to a cartridge packed with 30 mg MIP. The cartridge was washed 
with 2 mL CHCl3, followed by 2 mL MeOH. LPAs were eluted with 3 mL 0.05% 
NH4OH in MeOH. The solvent was evaporated under N2 stream and the residue was 
reconstituted in 0.2 mL MeOH-H2O 9:1. 
4.2.9 LC-ESI/MS procedure for plasma analysis 
Samples (10 µL) after the enrichment with SPE step were injected to a Luna C-8 
(50 × 2 mm, 3 µm) column at 40 ºC. The mobile phase, MeOH–HCOOH (pH 2.5) 9:1, 
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was delivered at a flow rate of 0.6 mL/min. Ions were created in negative ion mode by 
setting the sprayer voltage at 3.0 kV and the capillary temperature at 300 ºC. 
4.2.10 Swelling of polymers 
Dry polymer was placed in a 10 mL graduated cylinder and weighed. The weight 
and volume of the dry polymer were used to calculate the density of the polymer. Excess 
CHCl3 was added and air bubbles removed by stirring. The polymer was allowed to swell 
for 24 h. The swelling factor was calculated as the ratio of the volume of the swollen 
polymers to the dry polymers.  
4.3 Results and discussion 
4.3.1 Monomer selection and synthesis 
Functional monomers and crosslinking monomers were selected from a virtual 
library of 22 functional monomers containing functionalities for phosphate binding and 7 
crosslinking monomers. A Leapfrog algorithm from Tripos Inc. was used to determine 
the binding of the functional monomer candidates and target analyte LPA 18:0.  
Functional monomers with the highest binding score and crosslinking monomers with the 
lowest binding score were selected as the best candidates for polymer preparation. 
Selected functional monomers 1-5 are shown in Figure 4.10.  Monomer 1-4 are 
synthesized following the protocols in literature. The synthesis schemes are shown in 
Scheme 4.1-4.3. 
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Figure 4.10  Chemical structures of selected functional monomers. 
 
Scheme 4.1  Synthesis of monomer 1. 
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Scheme 4.2  Synthesis of monomer 2. 
 
Scheme 4.3  Synthesis of monomer 3 and 4. 
4.3.2 Characterization of monomer binding properties 
To study the binding properties of monomer 1, octadecylphosphonic acid was 
used as the anionic guest. Octadecylphosphonic acid was also selected as the template for 
imprinting instead of LPA, to avoid interfering from potential LPA residue after template 
extraction. Weakly polar aprotic solvent chloroform was used as the solvent to avoid 
hydrogen bonding between the solvent and the template or the monomers. Data and 1H-
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NMR spectra of the Job plot are shown in Table 4.1 and Figure 4.11. The binding affinity 
of the urea functional group to the phosphate group was monitored using 1H NMR. 
Downfield chemical shift of the urea N-H group and adjacent methylene protons were 
observed and monitored. Based on the results from Job plots, the maximum chemical 
shift was obtained when the mole ratio of monomer and guest was 1:1. Job plot is shown 
in Figure 4.12.  
  
7
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Table 4.1  Data for the Job plot performed by 1H NMR titration in CDCl3. 
Mixture 
No. 
Monomer 1 (mM) Template (mM) Mole fraction (monomer 1) δ (ppm) ∆δ (ppm) ∆δ × Mole fraction 
1 10 0 1 3.1683 0.0000 0.0000 
2 9 1 0.9 3.1901 2.1683 0.0196 
3 8 2 0.8 3.2291 2.1901 0.0486 
4 7 3 0.7 3.2784 2.2291 0.0770 
5 6 4 0.6 3.3346 2.2784 0.0998 
6 5 5 0.5 3.4273 2.3346 0.1295 
7 4 6 0.4 3.4633 2.4273 0.1180 
8 3 7 0.3 3.5123 2.4633 0.1032 
9 2 8 0.2 3.5538 2.5123 0.0771 
10 1 9 0.1 3.5563 2.5538 0.0388 
11 0 10 0 - - - 
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Figure 4.11  1H NMR spectra of Job plot data for trisurea and octadecylphosphonic acid. Each spectrum is labeled with the mixture 
numbers in Table 3.1.
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Figure 4.12  Job plot of monomer 1 with octadecylphosphonic acid in CDCl3 showing a 
maximum at 0.5 mole fraction of trisurea. 
 
The 1H NMR titration experiment in CDCl3 was carried out to determine the 
association constant of monomer 1 and octadecylphosphonic acid.  Data and results are 
shown in Table 4.2 and Figure 4.13. 1H NMR titration of monomer 1 using 
octadecylphosphonic acid as the guest is shonw in Figure 4.14. The association constant 
K is calculated to be 83.17 M-1. 
Job plot and NMR titration experiments were also done using monomer 
methacrylic acid as the host and octadecylphosphonic acid as the guest. No chemical shift 
was observed for the proton in N-H group or the adjacent methylene groups.  
  
7
5
Table 4.2  Data of 1H NMR titration of monomer 1 with template in CDCl3. 
Mixture No. Monomer 1 (mM) Template (mM) ∆δ (ppm) ∆δ (ppm) ∆δ (ppm) 
1 5 0 0 0 0 
2 5 0.5 0.12 0.02 0.06 
3 5 1 0.19 0.04 0.1 
4 5 1.5 0.26 0.07 0.16 
5 5 2 0.33 0.09 0.2 
6 5 3 0.46 0.13 0.29 
7 5 4 0.6 0.17 0.38 
8 5 5 0.64 0.21 0.47 
9 5 7.5 0.66 0.29 0.64 
10 5 10 
 
0.33 0.74 
11 5 15  0.37 0.84 
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Figure 4.13  1H NMR titration spectra of trisurea and octadecylphosphonic acid. Each spectrum is labeled with the mixture number in Table 3.2. 
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Figure 4.14  1H NMR titration of monomer 1 using octadecylphosphonic acid as the guest. 
 
4.3.3 Infrared spectroscopy of MIP 
Fourier transform infrared spectroscopy (FTIR) spectra of the non-imprinted 
polymer and imprinted polymer after template removal were collected and shown in 
Figure 4.15. IR of non-imprinted polymer, 3547, 3377, 2961, 1713, 1547, 1445, 1382, 
1236, 1126, 1039, 938, 841, 806, 745 cm-1. IR of imprinted polymer after template 
removal, 3531, 3375, 2943, 1714, 1632, 1551, 1448, 1384, 1242, 1137, 1043, 943, 845, 
784, 748 cm-1.  No phosphate group peaks were observed in the spectrum of imprinted 
polymer, because 95 % of the octadecylphosphonic acid was removed in the template 
extraction step.  
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Figure 4.15  IR spectra of (a) non-imprinted polymer and (b) imprinted polymer after template 
removal. 
4.3.4 SEM microphotographs of polymers  
A scanning electron microscope (SEM) microphotographs in Figure 4.16 show 
that both non-imprinted and imprinted polymers obtained from bulk polymerization are 
irregular shaped particles. 
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(a) 
 
(b) 
Figure 4.16  SEM microphotographs of non-imprinted (a) and imprinted (b) polymers. 
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4.3.5 Swelling of polymers 
Swelling factors and density of MIP and NIP are shown in Table 4.3. 
Table 4.3  Swelling factor and density of non-imprinted and imprinted polymers. 
 Non-imprinted polymer Imprinted polymer 
Density 0.331 g/mL 0.647 g/mL  
Swelling factor 2.05 3.47 
Monomer 1 was firstly synthesized and used as the functional monomer in the 
MIP preparation. Optimization of the formulations was carried out after promising 
screening results were obtained. MIP with monomer 2 was also prepared and screened. 
The binding of LPA to the polymer was also quite strong, necessitating further study. 
MIP with monomer 4 as the functional monomer was not prepared because the complex 
formed by this monomer and the template octadecylphosphonic acid could not be 
dissolved in any aprotic solvent.   
4.3.6 Formulation optimization of MIP 
Other functional monomers including 2-vinylpyridine, 4-vinylpyridine (4-VP), 
and 1-allylthiourea were also evaluated for LPA binding. However, the template OPA did 
not dissolve completely in CHCl3 at the desired concentration; and the addition of the 
functional monomer did not help to dissolve the template under the conditions used for 
template-monomer complex formation. A bulk polymerization procedure was chosen. 
Soxhlet extraction of the polymer pieces removed 95 % of the template from the 
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imprinted polymer. An optimal MIP should afford high recovery and high selectivity for 
LPA.  
A series of MIPs formulations were prepared as shown in Table 4.4. The first 
formulation attempted (Table 4.4, entry 1) included only monomer 1 as the functional 
monomer.  Screening results for this formulation showed that 60-80% of each individual 
LPA could be recovered, but 70-80% of PA was bound to the polymer and co-eluted with 
LPA from the MIP. Because of the high cross-reactivity observed between PA and LPA, 
a second monomer was included in the formulation. For this purpose, methacrylic acid 
(MAA) and 4-vinylpyridine (4-VP) were used in order to increase non-covalent 
interactions via hydrogen bonding. 
In the presence of MAA in the formulation, (Table 4.4, entry 2) the recovery of 
PA was lowered by 50% due to the absence of the hydroxyl group in the PA structure. 
The recovery of LPA was also increased to 70-115 %. The formulation containing, 4-VP, 
(Table 4.4, entry 3) as the second monomer, showed a similar LPA recovery to the 
second formulation, but with less selectivity. Thus, the second formulation (Table 4.4, 
entry 2) was found to have the best required properties for the purpose of this study. A 
comparison of percent recoveries of LPA and possible interferences in preliminary 
screening experiments with all three formulations of MIP are shown in Figure 4.18.   
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Figure 4.17  Structures of OPA, MAA, 4-vinylpyridine, EGDMA and AIBN.
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Table 4.4  Formulations of MIP and NIP.  
Entry Polymer Template 
Functional 
monomer 1 
Functional 
monomer 2 
Crosslinking 
monomer 
Initiator Solvent 
1 
NIP-1 － 
Monomer 1 
(0.81 M) 
－ 
EGDMA  
(16.2 M) 
AIBN 
 (0.41 M) 
CHCl3 
MIP-1 
OPA  
(0.81 M) 
Monomer 1 
(0.81 M) 
－ 
EGDMA  
(16.2 M) 
AIBN  
(0.41 M) 
CHCl3 
2 
NIP-2 － 
Monomer 1 
(0.81 M) 
MAA (0.81 M) 
EGDMA  
(16.2 M) 
AIBN  
(0.41 M) 
CHCl3 
2 
MIP-2 
OPA 
 (0.81 M) 
Monomer 1 
(0.81 M) 
MAA (0.81 M) 
EGDMA 
 (16.2 M) 
AIBN  
(0.41 M) 
CHCl3 
3 
NIP-3 － 
Monomer 1 
(0.81 M) 
4-VP (0.81 M) 
EGDMA  
(16.2 M) 
AIBN  
(0.41 M) 
CHCl3 
MIP-3 
OPA 
 (0.81 M) 
Monomer 1 
(0.81 M) 
4-VP (0.81 M) 
EGDMA  
(16.2 M) 
AIBN 
 (0.41 M) 
CHCl3 
Structures of OPA, MAA, 4-vinylpyridine, EGDMA and AIBN are shown in Figure 4.17. 
 
  
8
4
 
Figure 4.18  Percent recoveries of LPA and possible interferences in preliminary screening experiments of three formulations of MIP. 
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4.3.7 SPE protocol optimization 
The MIP showed a good binding affinity with LPA in organic media. About 75 % 
of each LPA subspecies were bound to MIP in a CHCl3-MeOH mixture. Formic acid was 
added to protonate LPA, and increased the binding to 95 %.  MeOH or CHCl3 alone 
could only elute 60-70% of the bound LPA from the MIP. However, more than 90 % of 
the LPA could be eluted with 0.05% NH4OH in MeOH. CHCl3 followed by MeOH was 
used in the washing step for the removal of neutral phospholipids, such as LPC, PC, etc. 
Using CHCl3 in the washing removed only 50 % LPC; MeOH removed the remainder. 
From the evaluation results, we noticed that the non-imprinted polymer showed a 
stronger binding property to PA than the imprinted polymer under the same loading and 
elution conditions.  About 80% of the PA was retained in the non-imprinted polymer 
(NIP-2), compared to 50% in the imprinted polymer (MIP-2) when samples were loaded 
in 0.05% HCOOH in CHCl3 and eluted in 0.05% NH4OH in MeOH. This can be 
interpreted as arising from the differences in selectivity between the non-imprinted and 
imprinted polymers. The non-imprinted polymer has no selectivity in its binding to 
phosphate head groups, while the imprinted polymer contains cavities that are specific 
shaped for LPA molecules. This imprinting effect allows us to use the non-imprinted 
polymer to retain PA before the sample was loaded to the imprinted polymer. On the 
other hand, LPA was not retained in the non-imprinted polymer because of less non-
specific interaction with the polymer compare to PA, which has (double) fatty acid chains. 
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4.3.8 LPA extraction and quantification in plasma 
Mixtures of LPA 14:0, LPA 20:4, LPA 16:0, LPA 18:1 and LPA 18:0 with 
concentrations ranging from 0.5-10 µM were evaluated with non-natural LPA 17:0 as an 
internal standard. All LPAs showed linear responses in this range.  Statistical values from 
calibration curves are shown in Table 4.5. Calibration curves of LPA species are shown 
in Figure 4.19. For all LPA species, acceptable correlation factors (R2) were obtained. 
The limit of detection (LOD) was determined as the amount of analyte that corresponds 
to three times the signal of the background noise. 
Table 4.5  Statistical values from calibration curves for LPA species using LC/MS as the 
quantification method. 
LPA species Retention time (min) Equation R2 LOD (µM) 
14:0 3.78 y = 0.0804x + 0.0164 0.9958 0.126 
20:4 4.41 y = 0.0939x + 0.0219 0.9941 0.153 
16:0 4.87 y = 0.0821x + 0.0156 0.9972 0.166 
18:1 5.32 y = 0.0775x + 0.0156 0.9954 0.182 
18:0 6.60 y = 0.0734x + 0.0114 0.9967 0.225 
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Figure 4.19  Calibration curves of LPA subspecies with LC/MS as the quantification 
method. The area ratio is the peak area of individual LPA divided by the peak area of the 
internal standard (LPA 17:0). Data points represent the average of 3 runs. 
The recoveries of LPA were determined using LPA control samples and the 
results are summarized in Table 4.6. Hexadecylphosphonic acid (5 µM) was used as an 
internal standard instead of octadecylphosphonic acid to eliminate the potential interfere 
from the residue of template in MIP. Two concentration LPA mixtures including 0.5 µM 
and 2.5 µM were evaluated for three times. 
Table 4.6  Recoveries of individual LPA species after SPE. (n = 3) 
LPA species Recovery (%) σ 
14:0 87.1 1.5 
20:4 86.2 1.6 
16:0 89.5 1.4 
18:1 87.6 1.5 
17:0 85.1 1.6 
18:0 87.3 1.3 
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Plasma samples and plasma samples spiked with 0.5 µM, 1 µM and 2 µM of each LPA subspecies were used to evaluate the 
method and determine potential matrix interferences.  All samples were prepared and analyzed in triplicates. Results of non-spiked 
plasma samples and spiked samples are summarized in Table 4.7. Representative HPLC traces of plasma sample and LPA control 
sample are shown in Figure 4.20.  
Table 4.7  Results for LPA analysis in human plasma using LC-ESI/MS. 
LPA species Non-spiked Spiked with 0.5 µM Spiked with 1 µM Spiked with 2 µM 
average σ average σ % recovery average σ % recovery average σ % recovery 
14:0 0.25 0.02 0.70 0.03 91.23 1.19 0.03 94.59 2.16 0.04 95.83 
20:4 0.23 0.02 0.74 0.01 103.10 1.25 0.06 101.84 2.26 0.02 101.44 
16:0 0.37 0.02 0.93 0.04 111.56 1.42 0.05 105.17 2.45 0.03 103.98 
18:1 0.26 0.03 0.78 0.03 103.24 1.29 0.04 103.28 2.30 0.04 101.91 
18:0 0.34 0.01 0.87 0.02 106.34 1.36 0.05 101.70 2.39 0.22 102.62 
Total LPA 1.45 0.05 4.02 0.07 103.09 6.51 0.10 101.32 11.56 0.23 101.16 
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Figure 4.20  LC-ESI/MS traces. (a) A 10 uM standard mixtures of LPAs. (b) Plasma sample. Column: Luna TM C-8 (50 × 2 mm, 3 µm) at 40 ºC.  
Injection volume: 10 µL. Mobile phase: 9:1 MeOH–HCOOH (pH 2.5). Flow rate:  0.6 mL/min. Ions were detected in negative ion mode. 
Sprayer voltage: 3.0 kV and Capillary temperature at 300 ºC 
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To determine the existence of non-LPA phospholipids in the plasma extraction 
after SPE with NIP and MIP, an LC/MS full scan in negative and positive modes was 
used. A mixture of phospholipids was used as the control sample and confirmed to be 
detectable in either negative or positive mode. The plasma sample after extraction was 
tested using the same method. Signals were compared to the LIPID MAPS Structure 
Database (LMSD)64.  No interfering phospholipids except traces amount of LPC could be 
detected. Using the presence of LPC 15:0 as the internal standard, the concentration of 
LPC 16:0, LPC 18:1 and LPC 18:0 were estimated to be 0.05 µM, 0.01 µM and 0.02 µM, 
respectively. The level represents less than 0.1 % of the total physiological LPC in human 
plasma.73 This result is comparable to our previous method 70. 
4.4 Conclusion 
The MIP prepared using monomer 1 and methacrylic acid as functional 
monomers showed significant advantages for LPA extraction and enrichment in 
selectivity.  Using this MIP as an SPE cartridge stationary phase allows fast and simple 
extraction of LPA from human plasma with high recoveries and high purities. Compared 
to the previous extraction method we developed70, the current method is faster and less 
labor intensive, because most of the vortexing and centrifugation steps in liquid-liquid 
extraction are replaced. The extraction and quantification of plasma LPA can be 
automated easily because of the elimination of liquid-liquid extraction.  
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Chapter 5 Future Work 
 
5.1 Optimization of current formulations of MIP 
Synthesize MIPs with a more optimized formulation (e.g., stoichiometries of 
monomers) to remove PA completely without passing the sample through the extra 
SPE filled with NIP. This may be realized by adding more hydrophobic crosslinking 
monomer to retain PA that contains double fatty chains. We could also attempt by 
modify the ratio of functional monomers and crosslinking monomers in the 
formulation.  
5.2 MIP with other functional monomers  
Synthesize and evaluate MIPs with other functional monomers, such as 
monomers 2-5 in Chapter 4.  MIPs with other functional monomers could possibly 
be more advantageous for simplifying LPA extraction. For example, MIPs that could 
be used in aqueous media could enable bypassing bypassing treatment with MeOH 
and CHCl3. In other words, the plasma could potentially be passed directly through a 
MIP cartridge if the MIP effectively binds LPA in water. To date, a MIP with 1-
vinylimidazole as the functional monomer showed good binding affinity to LPA 
(>90 % LPA bound; however, elution was problematic) according to preliminary 
screening results.  
5.3 MIP for specific LPA subspecies 
The MIP we are currently using is selective for LPA over other 
phospholipids, but is not selective for individual LPA species. The synthesis of MIPs 
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for each individual LPA can eliminate separation with HPLC, which will simplify 
and shorten the analysis. Individual subspecies quantification could also be 
accomplished directly with fluorescence. 
5.4 Molecularly imprinted membrane (MIM) for LPA analysis 
Along with MIPs, we can also synthesize MIMs for selective LPA analysis. 
Plasma LPA extractions with MIM as a filter could be advantageous because of the 
potentially shorter retention time of LPA in the material. Functional monomers, 
described herein could also be used as a starting point for creating LPA-selective 
MIMs. 
5.5 MIPs with fluorescent probes 
MIPs that contain fluorescence probes within their interior could allow for 
the direct determination of LPA in plasma via an optical signal. Fluorescence probes 
that have been synthesized specifically for LPA detection in our research group can 
be modified with vinyl groups and be incorporated during polymerization.  
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